Tumor- and Fibroblast-Derived Cell-Free DNAs Differently Affect the Progression of B16 Melanoma In Vitro and In Vivo
-
Published:2024-05-13
Issue:10
Volume:25
Page:5304
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Filatova Alina A.12ORCID, Alekseeva Ludmila A.1ORCID, Sen’kova Aleksandra V.1ORCID, Savin Innokenty A.1ORCID, Sounbuli Khetam12ORCID, Zenkova Marina A.1ORCID, Mironova Nadezhda L.1ORCID
Affiliation:
1. Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences (SB RAS), Lavrentiev Ave., 8, Novosibirsk 630090, Russia 2. Faculty of Natural Sciences, Novosibirsk State University, Novosibirsk 630090, Russia
Abstract
It is widely postulated that the majority of pathologically elevated extracellular or cell-free DNA (cfDNA) in cancer originates from tumor cells; however, evidence has emerged regarding the significant contributions of other cells from the tumor microenvironment. Here, the effect of cfDNA originating from murine B16 melanoma cells and L929 fibroblasts on B16 cells was investigated. It was found that cfDNAL929 increased the viability and migration properties of B16 cells in vitro and their invasiveness in vivo. In contrast, cfDNAB16 exhibited a negative effect on B16 cells, reducing their viability and migration in vitro, which in vivo led to decreased tumor size and metastasis number. It was shown that cell treatment with both cfDNAs resulted in an increase in the expression of genes encoding DNases and the oncogenes Braf, Kras, and Myc. cfDNAL929-treated cells were shown to experience oxidative stress. Gene expression changes in the case of cfDNAB16 treatment are well correlated with the observed decrease in proliferation and migration of B16 cells. The obtained data may indicate the possible involvement of fibroblast DNA in the tumor microenvironment in tumor progression and, potentially, in the formation of new tumor foci due to the transformation of normal cells.
Funder
Russian Science Foundation Russian State-funded budget project of ICBFM
Reference52 articles.
1. The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring;Batool;Cell Rep. Med.,2023 2. Bridging biological cfDNA features and machine learning approaches;Moser;Trends Genet.,2023 3. Dao, J., Conway, P.J., Subramani, B., Meyyappan, D., Russell, S., and Mahadevan, D. (2023). Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation. Int. J. Mol. Sci., 24. 4. Li, Y., Fan, Z., Meng, Y., Liu, S., and Zhan, H. (2023). Blood-based DNA methylation signatures in cancer: A systematic review. Biochim. Biophys. Acta Mol. Basis Dis., 1869. 5. Li, Y.Z., Kong, S.N., Liu, Y.P., Yang, Y., and Zhang, H.M. (2023). Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?. J. Clin. Med., 12.
|
|